The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The expanding therapeutic landscape of R/R multiple myeloma
Tarek H Mouhieddine, MD, Icahn School of Medicine at Mount Sinai, New York, NY, talks on emerging immunotherapeutic options for patients with multiple myeloma who are refractory to immunomodulatory drugs (IMiDs), anti-CD38 monoclonal antibodies and proteasome inhibitors. In particular, chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are highly promising treatment options for patients with triple-class and penta-refractory multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
